BeiGene, Ltd. announced that, following approval by its shareholders and satisfaction of other closing conditions, the global strategic oncology collaboration with Amgen previously announced on October 31, 2019, has become effective and Amgen has completed its purchase of an approximately 20.5% equity stake in BeiGene. Under the terms of the collaboration, BeiGene will assume responsibility for the commercialization and development in China of Amgen's three oncology medicines, XGEVA® (denosumab), KYPROLIS® (carfilzomib), and BLINCYTO® (blinatumomab) that have been approved or filed in China. BeiGene and Amgen will collaborate to advance 20 investigational oncology assets in Amgen's pipeline, with BeiGene leading development and commercialization in China.

Amgen purchased 15,895,001 of BeiGene's American Depositary Shares (representing 206,635,013 ordinary shares) for approximately $2.8 billion in cash.